Glimepiride
InterventionApproved 19952 papers1 findingPubChem 3476ChEBI 5383MeSH C057619
- Human trial1
Outcomes
1Branched-chain amino acids
downin humans1Moderate certainty
1 study
Branched-chain amino acids
downin humans1Moderate certainty
Glimepiride decreases branched-chain amino acids in humans.
Human trialtype 2 diabetes and biopsy-confirmed MASLDliver48 weeks
Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study · Biochemistry and biophysics reports · 14 Sep 2026
Trials
93Approved
30 Nov 1995 · Discontinued
In trials
Phase 4 · Results posted · 69 trials
Phase 4 · Results posted · 20 trials
Phase 4 · Completed · 4 trials
Phase 4 · Results posted · 2 trials
Phase 4 · Completed · 1 trial
Phase 4 · Completed · 1 trial
All 16Fewer
Phase 4 · Completed · 1 trial
Phase 4 · Completed · 1 trial
Glucose Metabolism Disorders
Phase 3 · Results posted · 2 trials
Phase 3 · Results posted · 1 trial
Phase 3 · Results posted · 1 trial
Phase 3 · Results posted · 1 trial
Phase 3 · Results posted · 1 trial
Phase 3 · Results posted · 1 trial
Phase 2 · Completed · 1 trial
Phase 2 · Results posted · 1 trial
Stopped
NCT03118713 · Terminated · Type 2 diabetes
Business decision due to enrollment challenges
Trial sponsors
Company15 trialsPhase 43,598 people
Company7 trialsPhase 44,178 people
Company6 trialsPhase 4727 people
Laboratorios Silanes S.A. de C.V.
Company4 trialsPhase 4226 people
Company3 trialsPhase 4728 people
Company2 trialsPhase 496 people
Company1 trialPhase 433 people
Company15 trialsPhase 36,860 people